Work

Encounters and medication use for ocular surface disorders among patients treated with dupilumab: A cohort study

Year: 2021

Type: article

Abstract: BACKGROUND: Although dupilumab has been associated with the development of conjunctivitis, little is known about other ocular surface disorders such as dry eye and how these side effects are managed. OBJECTIVE: To evaluate the incidence and management of ocular surface disorders, including dry eye and conjunctivitis, among patients treated with dupilumab. METHODS: Using US claims data, we evaluated the incidence of encounters for ocular surface disorders among patients treated with dupilumab. Secondary outcomes included ophthalmic medication use. A propensity score matched, active-comparator, new-user cohort design was used to compare the incidence of ocular surface disorders between those starting dupilumab versus methotrexate. RESULTS: < .001); 59.7% of those with a new ocular surface disorder diagnosis filled a prescription for an ophthalmic medication. The incidence of ocular surface disorders was higher among those treated with dupilumab than that in those treated with methotrexate (odds ratio 1.64; 95% confidence interval 1.17-2.30). LIMITATIONS: Observational design. CONCLUSIONS: Dupilumab use for atopic dermatitis was associated with an increased risk of ocular surface disorders. Most patients who developed an ocular surface disorder received a prescription for an ophthalmic medication.

Source: JAAD International

DOI: 10.1016/j.jdin.2021.03.009

Authors: John S. Barbieri, Vatinee Y. Bunya, Mina Massaro-Giordano, David J. Margolis

Institution: University of Pennsylvania

Language: English

Topic: Ocular Surface and Contact Lens

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,500